Penumbra, Inc. (PEN)
322.80
+0.22
(+0.07%)
USD |
NYSE |
Sep 02, 16:00
322.11
-0.69
(-0.21%)
Pre-Market: 08:06
Penumbra Research and Development Expense (TTM) : 75.84M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 75.84M |
| March 31, 2026 | 79.09M |
| December 31, 2025 | 83.18M |
| September 30, 2025 | 85.68M |
| June 30, 2025 | 90.51M |
| March 31, 2025 | 92.23M |
| December 31, 2024 | 94.78M |
| September 30, 2024 | 96.72M |
| June 30, 2024 | 92.47M |
| March 31, 2024 | 89.06M |
| December 31, 2023 | 84.42M |
| September 30, 2023 | 80.44M |
| June 30, 2023 | 80.81M |
| March 31, 2023 | 78.83M |
| December 31, 2022 | 79.41M |
| September 30, 2022 | 113.45M |
| June 30, 2022 | 108.86M |
| March 31, 2022 | 107.04M |
| December 31, 2021 | 104.55M |
| September 30, 2021 | 72.00M |
| June 30, 2021 | 90.19M |
| March 31, 2021 | 92.68M |
| December 31, 2020 | 87.55M |
| Date | Value |
|---|---|
| September 30, 2020 | 80.96M |
| June 30, 2020 | 59.76M |
| March 31, 2020 | 53.00M |
| December 31, 2019 | 51.72M |
| September 30, 2019 | 49.73M |
| June 30, 2019 | 45.09M |
| March 31, 2019 | 39.82M |
| December 31, 2018 | 36.16M |
| September 30, 2018 | 33.70M |
| June 30, 2018 | 32.74M |
| March 31, 2018 | 32.64M |
| December 31, 2017 | 31.66M |
| September 30, 2017 | 29.37M |
| June 30, 2017 | 27.74M |
| March 31, 2017 | 25.91M |
| December 31, 2016 | 23.88M |
| September 30, 2016 | 23.25M |
| June 30, 2016 | 21.31M |
| March 31, 2016 | 19.84M |
| December 31, 2015 | 18.03M |
| September 30, 2015 | 16.62M |
| June 30, 2015 | 15.52M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Boston Scientific Corp. | 2.153B |
| Globus Medical, Inc. | 147.06M |
| Teleflex, Inc. | 195.47M |
| Abbott Laboratories | 3.128B |
| AngioDynamics, Inc. | 29.45M |